LITS

Lite Strategy Inc
LITS

1.89 USD
-0.03
1.56%
At close Updated Nov 28, 4:00 PM EST
Pre-market
After hours
1.86
-0.03
1.59%
1 day
-1.56%
5 days
11.83%
1 month
-2.07%
3 months
-63.65%
6 months
-9.57%
Year to date
-25.88%
1 year
-32.98%
5 years
-96.72%
10 years
-94.81%
 

About: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Employees: 4

Healthcare Biotechnology
0
Funds holding %
of 7,476 funds
Explore Fund Trends
–
Analysts bullish %
See Analyst Outlook
–
Positive news %
Check Journalist POV
Price charts implemented using Lightweight Charts™